| 151 |
12635450 | Galantamine hydrobromide: an agent for Alzheimer's disease. | 2003 Mar 1 |
3 |
| 152 |
12742124 | Development and validation of a liquid chromatographic-tandem mass spectrometric method for the determination of galantamine in human heparinised plasma. | 2003 Jun 15 |
1 |
| 153 |
14535624 | Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. | 2003 |
2 |
| 154 |
14594523 | Clinical experience of galantamine in dementia: a series of case reports. | 2003 |
1 |
| 155 |
14674789 | Clinical pharmacokinetics of galantamine. | 2003 |
1 |
| 156 |
15088511 | [Acetylcholinesterase inhibitors]. | 2003 Jul |
1 |
| 157 |
24944370 | Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on. | 2003 Apr |
2 |
| 158 |
12031351 | A non-cholinergic, trophic action of acetylcholinesterase on hippocampal neurones in vitro: molecular mechanisms. | 2002 |
2 |
| 159 |
12134305 | [Nicotinic Receptor, galantamine and Alzheimer disease]. | 2002 Jun 1-15 |
1 |
| 160 |
12139365 | The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. | 2002 Jun |
1 |
| 161 |
12140604 | Galanthamine as bis-functional ligand for the acetylcholinesterase. | 2002 Jun |
1 |
| 162 |
12162759 | Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. | 2002 |
1 |
| 163 |
12410061 | Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. | 2002 Sep-Oct |
2 |
| 164 |
12417371 | The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease. | 2002 Nov 15 |
1 |
| 165 |
12450245 | The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. | 2002 Oct-Nov |
1 |
| 166 |
12481195 | Nicotinic cholinergic modulation: galantamine as a prototype. | 2002 Winter |
1 |
| 167 |
12548360 | Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. | 2002 Sep |
1 |
| 168 |
11226635 | Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. | 2001 Mar 16 |
1 |
| 169 |
11230880 | Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. | 2001 Feb 1 |
1 |
| 170 |
11396871 | Pharmacokinetic rationale for switching from donepezil to galantamine. | 2001 |
2 |
| 171 |
11449566 | Accurate prediction of the bound conformation of galanthamine in the active site of Torpedo californica acetylcholinesterase using molecular docking. | 2001 |
1 |
| 172 |
11571763 | Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. | 2001 Sep |
1 |
| 173 |
11669505 | Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. | 2001 Aug |
2 |
| 174 |
11669506 | Maintaining cognitive function in Alzheimer disease: how effective are current treatments? | 2001 Aug |
1 |
| 175 |
11825333 | Current status and new developments with galantamine in the treatment of Alzheimer's disease. | 2001 Dec |
2 |
| 176 |
19811027 | Galantamine: a new treatment for Alzheimer's disease. | 2001 Nov |
1 |
| 177 |
19811047 | Use of acetylcholinesterase inhibitors in Alzheimer's disease. | 2001 Sep |
1 |
| 178 |
10749487 | High-performance liquid chromatography with on-line coupled UV, mass spectrometric and biochemical detection for identification of acetylcholinesterase inhibitors from natural products. | 2000 Mar 3 |
1 |
| 179 |
10762042 | Potent acetylcholinesterase inhibitors: design, synthesis and structure-activity relationships of alkylene linked bis-galanthamine and galanthamine-galanthaminium salts. | 2000 Apr 3 |
1 |
| 180 |
10971047 | Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. | 2000 Sep |
2 |
| 181 |
10971048 | Galantamine: additional benefits to patients with Alzheimer's disease. | 2000 Sep |
1 |
| 182 |
10971049 | Galantamine: therapeutic effects beyond cognition. | 2000 Sep |
1 |
| 183 |
11078030 | The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. | 2000 Oct |
1 |
| 184 |
11129124 | Galantamine: a review of its use in Alzheimer's disease. | 2000 Nov |
2 |
| 185 |
11261808 | Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. | 2000 |
1 |
| 186 |
10634129 | The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. | 1999 Dec |
2 |
| 187 |
9839013 | Potent acetylcholinesterase inhibitors: design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series. | 1998 Oct |
4 |
| 188 |
1914378 | Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. | 1991 Oct |
2 |
| 189 |
1926583 | [The effect of pH and reversible inhibitors on decarbamylation of acetylcholinesterase]. | 1991 May-Jun |
1 |
| 190 |
1954303 | Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. | 1991 Aug |
3 |
| 191 |
2355800 | Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. | 1990 |
2 |
| 192 |
5873635 | [Acetylcholinesterase and the bioelectrical activity of the brain under the action of eserine and galanthamine in animals with premesencephalic section of the brain]. | 1965 Oct |
1 |